THMO - ThermoGenesis Holdings Inc Stock Price, Fair Value and News

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

THMO Price Action

Last 90 days

-100%

Trailing 12 Months

-100%

THMO RSI Chart

THMO Valuation

EV/EBITDA

0.07

THMO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

THMO Fundamentals

THMO Revenue

Revenue (TTM)

9.6M

Rev. Growth (Yr)

6.42%

Rev. Growth (Qtr)

13.76%

THMO Earnings

Earnings (TTM)

-15.7M

Earnings Growth (Yr)

61.39%

Earnings Growth (Qtr)

73.67%

THMO Profitability

Operating Margin

19.81%

EBT Margin

-173.01%

Return on Equity

-1.6K%

Return on Assets

-156.02%

THMO Investor Care

Shares Dilution (1Y)

317.62%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.6M	0	0	0
2023	10.4M	9.6M	9.7M	9.4M
2022	10.4M	11.3M	10.2M	10.5M
2021	8.1M	8.0M	8.8M	9.3M
2020	13.3M	11.2M	9.5M	9.7M
2019	10.8M	13.1M	14.0M	13.0M
2018	11.4M	9.9M	9.9M	9.7M
2017	14.0M	14.5M	13.8M	12.8M
2016	12.7M	11.9M	12.9M	13.6M
2015	16.2M	16.0M	15.2M	13.9M
2014	16.3M	16.0M	16.0M	16.2M
2013	18.3M	18.0M	17.5M	17.2M
2012	19.9M	19.0M	18.3M	18.3M
2011	23.3M	23.4M	21.3M	20.2M
2010	0	23.1M	23.2M	23.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About ThermoGenesis Holdings Inc

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

CEO	Dr. Xiaochun Xu M.B.A., Ph.D.
WEBSITE	thermogenesis.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	40

ThermoGenesis Holdings Inc Frequently Asked Questions

What is the ticker symbol for ThermoGenesis Holdings Inc? What does THMO stand for in stocks?

THMO is the stock ticker symbol of ThermoGenesis Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ThermoGenesis Holdings Inc (THMO)?

As of Fri Dec 20 2024, market cap of ThermoGenesis Holdings Inc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of THMO stock?

You can check THMO's fair value in chart for subscribers.

Is ThermoGenesis Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether THMO is over valued or under valued. Whether ThermoGenesis Holdings Inc is cheap or expensive depends on the assumptions which impact ThermoGenesis Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for THMO.

What is ThermoGenesis Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, THMO's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. THMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ThermoGenesis Holdings Inc's stock?

In the past 10 years, ThermoGenesis Holdings Inc has provided -1 (multiply by 100 for percentage) rate of return.